Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Nishikawa

Showing results (51-60 of 197) with videos related to

Pageof 20
Sort By:
International Journal of Systematic and Evolutionary Microbiology|November 2, 2021
<i>Vescimonas</i> gen. nov., <i>Vescimonas coprocola</i> sp. nov., <i>Vescimonas fastidiosa</i> sp. nov., <i>Pusillimonas</i> gen. nov. and <i>Pusillimonas faecalis</i> sp. nov. isolated from human faecesMaki Kitahara, Yuko Shigeno, Mari Shime, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 1, 2004
[Diffuse large B-cell lymphoma of the knee occurring 70 years after tuberculous arthritis]Satoshi Ueno, Motoko Yamaguchi, Shoko Ogawa, et al.
Discover Oncology|April 19, 2022
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancerNoriko Goda, Shinsuke Sasada, Hideo Shigematsu, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signalSho Isoyama, Shigeyuki Mori, Daisuke Sugiyama, et al.
Cancer Research|July 18, 2008
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signalingHiroyoshi Nishikawa, Takuma Kato, Michiko Hirayama, et al.
Journal for Immunotherapy of Cancer|October 14, 2018
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8<sup>+</sup> T cells in the tumor microenvironmentYasuko Tada, Yosuke Togashi, Daisuke Kotani, et al.
International Journal of Hematology|January 28, 2021
A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patientsShurui Chen, Toru Kiguchi, Yasuyuki Nagata, et al.
Blood|November 8, 2007
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vectorHiroyoshi Nishikawa, Takemasa Tsuji, Elke Jäger, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 1, 2002
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]Kazuhiro Nishii, Hidetsugu Mitani, Hiroyuki Miyashita, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Tumor-specific crosslinking of GITR as costimulation for immunotherapyTanja Burckhart, Markus Thiel, Hiroyoshi Nishikawa, et al.
Pageof 20

Showing results (51-60 of 197) with videos related to

Sort By:
Pageof 20
International Journal of Systematic and Evolutionary Microbiology|November 2, 2021
<i>Vescimonas</i> gen. nov., <i>Vescimonas coprocola</i> sp. nov., <i>Vescimonas fastidiosa</i> sp. nov., <i>Pusillimonas</i> gen. nov. and <i>Pusillimonas faecalis</i> sp. nov. isolated from human faecesMaki Kitahara, Yuko Shigeno, Mari Shime, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 1, 2004
[Diffuse large B-cell lymphoma of the knee occurring 70 years after tuberculous arthritis]Satoshi Ueno, Motoko Yamaguchi, Shoko Ogawa, et al.
Discover Oncology|April 19, 2022
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancerNoriko Goda, Shinsuke Sasada, Hideo Shigematsu, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signalSho Isoyama, Shigeyuki Mori, Daisuke Sugiyama, et al.
Cancer Research|July 18, 2008
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signalingHiroyoshi Nishikawa, Takuma Kato, Michiko Hirayama, et al.
Journal for Immunotherapy of Cancer|October 14, 2018
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8<sup>+</sup> T cells in the tumor microenvironmentYasuko Tada, Yosuke Togashi, Daisuke Kotani, et al.
International Journal of Hematology|January 28, 2021
A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patientsShurui Chen, Toru Kiguchi, Yasuyuki Nagata, et al.
Blood|November 8, 2007
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vectorHiroyoshi Nishikawa, Takemasa Tsuji, Elke Jäger, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 1, 2002
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]Kazuhiro Nishii, Hidetsugu Mitani, Hiroyuki Miyashita, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Tumor-specific crosslinking of GITR as costimulation for immunotherapyTanja Burckhart, Markus Thiel, Hiroyoshi Nishikawa, et al.
Pageof 20